In 92 breast cancer patients genotyped for the CBR3 gene, those with the CBR3 V244M variant had a significant reduction of LVEF six months after the initiation of doxorubicin, although the numerical reduction of LVEF was small [17]. This evidence concerns the gene CBR3 and breast carcinoma.